Prostate cancer: Is the future focal?

**Aims and objectives of this session**
The aim of this session is to update delegates on the use of focal therapy and non-whole gland treatments.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

---

**758**
**Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study**
**By:** Shanmugabavan Y.¹, Bass E.¹, Hulme A.², Freeman A.³, Brew-Graves C.¹, Potyka I.¹, Ramachandran N.⁴, Emberton M.¹, Ahmed H.U.¹

**Institutes:** University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, ²Sophiris, Sophiris Bio Corporation, California, United States of America, ³University College London Hospital, Dept. of Histopathology, London, United Kingdom, ⁴University College London Hospital, Dept. of Radiology, London, United Kingdom

**759**
**Impact of the use of N2O for general anesthesia during high intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer**
**By:** Potiron E.¹, Lacoste J.², Le Goguic G.², Rousseau T.², Nevoux P.²

**Institutes:** Clinique Urologique Nantes Atlantis, Dept. of , Saint Herblain, France, ²Clinique Urologique Nantes Atlantis, Dept. of, Saint Herblain, France

**760**
**Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy**
**By:** Garcia Barreras S.¹, Sanchez-Salas R.¹, Sivararam A.², Secin F.³, Redondo C.¹, Velilla G.¹, Barret E.¹, Nunes-Silva I.¹, Srougi V.¹, Baghdadi M.¹, Galiano M.¹, Rozet F.¹, Cathala N.¹, Mombet A.¹, Prapotnich D.¹, Cathelineau X.¹

**Institutes:** Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ²Memorial Sloan Kettering, Dept. of Urology, New York, United States of America, ³CEMIC, Dept. of Urology, Buenos Aires, Argentina

**761**
**A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study**
**By:** Leslie T.¹, Elliott D.¹, Le Conte S.¹, Brewster S.², Sooriakumaran P.¹, Bryant R.¹, Dudderidge T.⁴, Rosario D.³, Catto J.⁵, Hindley R.⁶, Emberton M.⁷, Ahmed H.¹, Donovan J.², Hamdy F.¹

**Institutes:** Oxford University - Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, ²Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, ³University of Bristol, Dept. of Social and Community Medicine, Bristol, United Kingdom, ⁴University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ⁵Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, ⁶Basingstoke and North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom, ⁷University College London Hospital, Dept. of Urology, London, United Kingdom

**762**
**First repeated biopsy represents the most informative predictor of progression-free survival at 3**
A nomogram for prediction of local cancer recurrence after primary prostate cryoablation
By: El Shafei A.¹, Tay K.J.², Ross A.³, Given R.⁴, Parsons J.K.⁵, Mouraviev V.⁶, Polascik T.⁷, Jones J.S.⁸
Institutes: ¹Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, ²Duke Cancer Institute, Dept. of Urology, Durham, United States of America, ³The Johns Hopkins Medical Institutions, Dept. of Urology, Baltimore, United States of America, ⁴Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, ⁵UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ⁶Global Robotics Institute, Dept. of Urology, Celebration, United States of America

MRI-guided transurethral ultrasound ablation in patients with localized prostate cancer: 24-month outcomes of a prospective phase I clinical trial
By: Chin J.¹, Relle J.², Billia M.³, Siddiqui K.M.⁴, Kuru T.⁵, Hatiboglu G.⁶, Ionel V.P.⁷, Hafron J.⁵, Matthias R.⁸, Mueller-Wolf M.⁹, Zahra K.¹⁰, Kibria F.¹¹, Burltyk M.¹², Schlemmer H-P.¹³, Pahernik S.¹³
Institutes: ¹Western University, Dept. of Urology, London, Canada, ²Beaumont Health System, Department of Urology, Dept. of Urology and Radiology, Royal Oak, United States of America, ³German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, ⁴Profound Medical Inc., Dept. of Engineering, Toronto, Canada

Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymph vessel invasion and shortens biochemical recurrence-free survival periods
By: Miyata Y.¹, Mochizuki Y.², Shida Y.³, Matsuo T.⁴, Hakariya T.⁴, Ohba K.⁴, Furusato B.², Fukuoka J.³, Sakai H.¹
Institutes: ¹Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, ²Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

Salvage prostate cryoablation in older men
By: Parsons K.², Ross A.³, El Shafei A.¹, Hatem A.¹, Cotta B.², Tay K.J.², Polascik T.⁴, Given R.⁵, Mouraviev V.⁶, Jones J.S.⁸
Institutes: ¹Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, ²UC San Diego Health System, Dept. of Urology, San Diego, California, United States of America, ³The Johns Hopkins Medical Institutions, Dept. of Urology, Baltimore, United States of America, ⁴Duke Cancer Institute, Dept. of Urology, Durham, United States of America, ⁵Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, ⁶Global Robotics Institute, Dept. of Urology, Celebration, United States of America

Current national trends in the management of locally advanced prostate cancer with radical therapies: Results from the English National Prostate Cancer Audit
By: Sujenthiran A.¹, Nossiter J.², Charman S.³, Aggarwal A.¹, Cathcart P.², Payne H.³, Clarke N.⁴, Van Der Meulen J.¹
Institutes: ¹Royal College of Surgeons, Clinical Effectiveness Unit, London, United Kingdom, ²Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³University College London Hospitals, Dept. of Oncology, London, United Kingdom, ⁴The Christie and Salford Royal NHS Foundation Trusts, Dept. of Urology, London, United Kingdom
MRI/US fusion office-based targeted cryoablation with local anesthesia


Institutes: Urological Research Network, Dept. of Urology, Miami Lakes, United States of America

Summary

E. Barret, Paris (FR)